Satraplatin(Synonyms: 沙铂; BMS182751; BMY45594; JM216)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Satraplatin (Synonyms: 沙铂; BMS182751; BMY45594; JM216) 纯度: 99.82%

Satraplatin 是一种烷化剂 (alkylator)，具有抗肿瘤效果。

Satraplatin(Synonyms: 沙铂; BMS182751; BMY45594; JM216)

Satraplatin Chemical Structure

CAS No. : 129580-63-8

规格 价格 是否有货 数量
5 mg ￥3500 In-stock
10 mg ￥5000 In-stock
50 mg 询价
100 mg 询价

* Please select Quantity before adding items.

Satraplatin 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus

生物活性

Satraplatin is an alkylating agent, with potent antitumor effect.

体外研究
(In Vitro)

Satraplatin needs to avoid light in the solution, and it is unstable in the alkaline state but stable in the acidic state.
Satraplatin has potent antitumor activity. Satraplatin combined with dichloroacetate (DCA) inhibits UMC-11 cells with an IC50 of 1.36 ± 0.11 μM[1]. Satraplatin also suppresses CDDP-resistant (KB-R) cells (IC50, 7.04 μM), and causes G2/M arrest in KB-R cells[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

500.28

Formula

C10H20Cl2N2O4Pt
CAS 号

129580-63-8
中文名称

赛特铂；沙铂
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMF : 10 mg/mL (19.99 mM; ultrasonic and adjust pH to 1 with HCl; DMSO can inactivate Satraplatin’s activity)

H2O : < 0.1 mg/mL (insoluble; DMSO can inactivate Satraplatin’s activity)

Ethanol : < 1 mg/mL (insoluble; DMSO can inactivate Satraplatin’s activity)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.9989 mL 9.9944 mL 19.9888 mL
5 mM 0.3998 mL 1.9989 mL 3.9978 mL
10 mM 0.1999 mL 0.9994 mL 1.9989 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Fiebiger W, et al. In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines. Clin Transl Oncol. 2011 Jan;13(1):43-9.

    [2]. Yamano Y, et al. Antitumor activity of satraplatin in cisplatin-resistant oral squamous cell carcinoma cells. Head Neck. 2011 Mar;33(3):309-17.
Cell Assay
[1]

Cells are harvested, counted and distributed to microtiter plates in 100 μL medium at a density of 1×104 cells/well. Appropriate dilutions of test compounds (Satraplatin, etc.) are added to a total volume of 200 μL/well and plates incubated under tissue culture conditions for four days. Stock solutions of the compounds are prepared in either 70% ethanol or DMSO and diluted more than 100-fold for the assays. Solvent controls are included in all tests. Dose response curves are obtained by assessing cell proliferation at twofold drug dilutions in triplicate and used for calculation of IC50 values. Cell growth is quantified using a modified tetrazolium dye assay (MTT) and by measurement of the reduced formazane dye at 450 nm wavelength (medium control set to 100% proliferation)[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Fiebiger W, et al. In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines. Clin Transl Oncol. 2011 Jan;13(1):43-9.

    [2]. Yamano Y, et al. Antitumor activity of satraplatin in cisplatin-resistant oral squamous cell carcinoma cells. Head Neck. 2011 Mar;33(3):309-17.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务